Literature DB >> 7377665

Evidence of a modifying influence of heart glucosides on the development of breast cancer.

B Stenkvist, E Bengtsson, G Eklund, O Eriksson, J Holmquist, B Nordin, S Westman-Naeser.   

Abstract

Patients on digitalis medication at the time of diagnosis of breast cancer seem to develop tumors that have a lower growth potential than do patients not on such medication. These tumors are photometrically characterized by small nuclei with lower DNA-RNA content and less variation in morphometric characteristics.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7377665

Source DB:  PubMed          Journal:  Anal Quant Cytol        ISSN： 0190-0471


  15 in total

1.  Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.

Authors:  Bishoy A Gayed; Katherine J O'Malley; Jan Pilch; Zhou Wang
Journal:  Clin Transl Sci       Date:  2012-02-23       Impact factor: 4.689

2.  Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.

Authors:  Brian A Keller; Brian J Laight; Oliver Varette; Aron Broom; Marie-Ève Wedge; Benjamin McSweeney; Catia Cemeus; Julia Petryk; Bryan Lo; Bruce Burns; Carolyn Nessim; Michael Ong; Roberto A Chica; Harold L Atkins; Jean-Simon Diallo; Carolina S Ilkow; John C Bell
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-08       Impact factor: 4.553

Review 3.  Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials.

Authors:  M Slingerland; C Cerella; H J Guchelaar; M Diederich; H Gelderblom
Journal:  Invest New Drugs       Date:  2013-06-10       Impact factor: 3.850

4.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

5.  Changes in sodium pump expression dictate the effects of ouabain on cell growth.

Authors:  Jiang Tian; Xin Li; Man Liang; Lijun Liu; Joe X Xie; Qiqi Ye; Peter Kometiani; Manoranjani Tillekeratne; Runming Jin; Zijian Xie
Journal:  J Biol Chem       Date:  2009-03-27       Impact factor: 5.157

6.  Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells in vitro.

Authors:  C I Delebinski; S Georgi; S Kleinsimon; M Twardziok; B Kopp; M F Melzig; G Seifert
Journal:  Cell Prolif       Date:  2015-08-24       Impact factor: 6.831

7.  First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Authors:  D S Hong; H Henary; G S Falchook; A Naing; S Fu; S Moulder; J J Wheler; A Tsimberidou; J B Durand; R Khan; P Yang; M Johansen; R A Newman; R Kurzrock
Journal:  Invest New Drugs       Date:  2014-06-13       Impact factor: 3.850

Review 8.  Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression.

Authors:  Ebbe Boedtkjer
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

9.  Digitoxin and its analogs as novel cancer therapeutics.

Authors:  Hosam A Elbaz; Todd A Stueckle; William Tse; Yon Rojanasakul; Cerasela Zoica Dinu
Journal:  Exp Hematol Oncol       Date:  2012-04-05

10.  Trial watch: Cardiac glycosides and cancer therapy.

Authors:  Laurie Menger; Erika Vacchelli; Oliver Kepp; Alexander Eggermont; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.